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a b s t r a c tThe wide range of immunosuppressive therapies and protocols permits tailored planning of the initial regimen
according to the immunological risk status of individual patients. Pre-transplant risk assessment can include
many factors, but there is no clear consensus onwhich parameters to take into account, and their relative impor-
tance. In general younger patients are known to be at higher risk for acute rejection, compounded by higher rates
of non-adherence in adolescents. Donor age and recipient gender do not appear to exert a meaningful effect on
risk of rejection per se, but black recipient ethnicity remains awell-established risk factor evenundermodern im-
munosuppression regimens. Little difference in risk is now observed between deceased- and living-donor recip-
ients. Immunological risk assessment has developed substantially in recent years. Cross-match testing with
cytotoxic analysis has long been supplemented by ﬂow cytometry, but development of solid-phase single-bead
antigen testing of solubilized human leukocyte antigens (HLA) to detect donor-speciﬁc antibodies (DSA) permits
a far more nuanced stratiﬁcation of immunological risk status, including the different classes and intensities of
HLA antibodies Class I and/or II, including HLA-DSA. Immunologic risk evaluation is now often based on a com-
bination of these tests, but other assessments are becoming more widely introduced, such as measurement of
non-HLA antibodies against angiotensin type 1 (AT1) receptors or T-cell ELISPOT assay of alloantigen-speciﬁc
donor. Targeted densensitization protocols can improve immunological risk, notably for DSA-positive patients
with negative cytotoxicity andﬂowcross-match. HLAmismatch remains an important andundisputed risk factor
for rejection. Delayed graft function also increases the risk of subsequent acute rejection, and the early regimen
can be modiﬁed in such cases. Overall, there is a shift towards planning the immunosuppressive regimen based
on pre-transplant immunology testing although certain conventional risk factors retain their importance.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The transplant clinician can plan many different immunosuppres-
sive regimens for kidney transplant patients, tailored to each
speciﬁc need. With the immunosuppressive armamentarium now
including various induction therapies, calcineurin inhibitors (CNIs),
antiproliferative therapy (mycophenolic acid) and mammalian target
of rapamycin (mTOR) inhibitors, and several steroid dosing strategies,⁎ Corresponding author at: Department of General, Visceral, Vascular and Thoracic
Surgery Clinic of General, Visceral and Transplant Surgery, Charité - Universitätsmedizin
Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany. Tel.: +49 30 450 522 011;
fax: +49 30 450 522 912.
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http://dx.doi.org/10.1016/j.trre.2016.02.002
0955-470X/© 2016 The Authors. Published by Elsevier Inc. This is an open access article underindividualization according to particular patient proﬁles has become
more possible than ever before.
Unless clear risk factors for drug-speciﬁc side effects are present,
the key determinant when deciding upon a regimen is the patient's
immunological risk status and immunosuppression should be adapted
according to the risk for graft rejection [1]. However, although many
factors may contribute to a patient's risk status, only the number
of human leukocyte antigen (HLA) mismatches has been universally
agreed to increase risk [1] and the relative importance of other variables
often remains uncertain [2]. Recent clinical trials which have selectively
recruited ‘high risk’ patients have chosen different criteria for entry:
only sensitization based on panel reactive antibodies (PRA) have
been included consistently and, perhaps surprisingly, HLA mismatch
has not been included [3–8]. Additionally, development of singlethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Overview of early immunosuppression options after kidney transplantation according to
immunological risk status.
Immunologic risk
status
Comments
Induction Low/moderate risk IL-2R antagonist [1,24]
Higher riska T-cell depleting antibody [1,25,26]
CNI therapy Low/moderate risk CNI avoidance generally not advised
(possible with belatacept [27,28])
Low-exposure CNI + mTOR inhibitor
from time of transplant is feasible [29,30]
Higher riska Standard CNI protocol is generally
advisable
Steroid
avoidance
Low/moderate risk Early steroid avoidance (b7 days) is a
possibility with tacrolimus as CNI [31]
and induction is advisable [1]. T-cell
depleting antibody may be preferable to
IL-2RA induction [32–34]
Desensitizationb ABO incompatible
living-donor
transplants
Rituximab ± IVIG ± plasmapheresis or
immunoadsorption [22,23]
Sensitized patients
with DSA
IVIG ± rituximab ± plasmapheresis or
immunoadsorption [19–21] ± induction
with T-cell depleting antibody
a For example, retransplants, prior pregnancy, blood transfusion, HLA-antibody
positive.
b Usually in living donor transplantation.
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technology has, where available, considerably reﬁned the evaluation
of risk.
This article considers the contributions made by recipient, donor
and transplant factors toward the immunological risk status of kidney
transplant patients at the time of transplant, to assist clinicians
when planning the most appropriate immunosuppressive regimen for
individual recipients.
2. Impact of graft rejection
The incidence of acute rejection after kidney transplantation has de-
clined substantially since themid-1990s, stabilizing in recent years to be-
tween 10% and 25% by one year post-transplant depending on the level
of immunological risk [9,10]. A large US registry analysis based on data
from 2004 to 2007 indicates that acute rejection increases the risk of
death-censored graft survival by over 70% compared to rejection-free
transplants [11]. This, however, masks widely varying effects of different
types of acute rejection. The majority of episodes are mild cellular rejec-
tions (Banff grade I or IIA) andmay have little or no impact on graft out-
comes. Two large registry analyses from the mid-2000s [12,13] found
that in patients whose graft function recovers after rejection (for exam-
ple to N85% versus baseline), subsequent graft survival is unaffected. In-
stead, the effect of cellular rejection on graft survival is largely restricted
to more severe episodes without recovery of near-baseline function
[12,13] and late acute rejection (after month 3) [14].
An entirely different picture emerges concerning antibody-
mediated rejection (AMR), which is highly predictive for kidney graft
loss [15–17]. One analysis of biopsies in 56 patients who subsequently
progressed to graft failure found that AMR, ormixed AMR/cellular rejec-
tion,was present in 75% of cases [15]. Mixed rejection [17] and late AMR
(N6 months post-transplant) [18] are both difﬁcult to treat and carry a
particularly dismal prognosis, and even subclinical AMR signiﬁcantly
lowers graft survival rates [18].
It would seem that immunosuppressive regimens which carry a
slightly higher risk for mild, reversible cellular rejection may be accept-
able if they offer other beneﬁts, such as fewer long-term complications.
Where immunological risk is deemed to be high, however, this trade-off
is likely to be less successful. For patients at increased risk for AMR, the
importance of preventing AMR is paramount.
A detailed discussion of early immunosuppression options – and
longer-term regimens based on the post-transplant course – is beyond
the scope of this article. Key points, however, are summarized in Table 1.
3. Impact of recipient and donor demographics
Younger age at the time of transplantation increases the risk for
acute rejection [1], an effect attributed partly to age-related changes in
the T-cell effector immune response in older patients [35] and partly
due to lower adherence to the prescribed regimen (See ‘Adherence to
medication’ below). An analysis by Tullius et al. of over 100,000 kidney
transplant patients registered with the United Network for Organ Shar-
ing (UNOS) registry during 1995 to 2008 found that each successive de-
cade of age above 39 yearswas associatedwith a signiﬁcant reduction in
acute rejection during the ﬁrst year post-transplant (Fig. 1) [36,37]. An-
other large registry analysis, involving 27,707 patients transplanted in
the US during 1995 to 2002, showed that after adjustment for con-
founding factors, recipients aged 18–44 years were 23% more likely to
experience acute rejection by year 1 than those aged 44–59 years [38].
Other registry [39] and large single-center [15,40] analyses have consis-
tently reported younger age to predict risk for acute rejection.
Conversely, there is evidence that a graft from an older donor, pre-
sumably with greater immunogenicity, adversely affects risk of rejec-
tion [1]. The large UNOS analysis by Tullius and colleagues found that
acute rejection rates increased for donors aged older than 29 years
(Fig. 1) but the difference was not signiﬁcant for all age groups [36].Analyses of other data sets have shownmixed results [40–43] regarding
the relative impact of donor age on immunological risk, but overall
donor age is likely to play a less important role in risk assessment
than recipient age.
A potential inﬂuence for recipient gender on immunological risk re-
mains controversial. The largest population to be studied, a series of
27,707 patients from a US registry, found a higher risk of acute rejection
in male recipients [38] while non-registry studies have reported either a
higher risk in females [39,40] or nodifference [15,41]. The lack of consistent
data – and a paucity of results from recently transplanted cohorts – does
not support inclusion of gender per se in an immunological risk assessment
so long as females are not sensitized by previous pregnancies (see below).
Black recipient ethnicity is a well-established risk factor for acute
rejection after kidney transplantation even undermodern immunosup-
pression regimens [39,42,44]. African Americans have a higher frequen-
cy of CYP 3 A5 polymorphism (CYP4503A5*1 genotype), which is
associated with low tacrolimus exposure for a given dose [45], contrib-
uting to an increased risk for rejection. A prospective, multicenter study
of 901 patients given tacrolimus and mycophenolic acid maintenance
therapy found the one-year incidence of biopsy-proven acute rejection
(BPAR) to be approximately twice as high in African-American versus
non-African American patients (14.1% versus 7.5%; hazard ratio [HR]
1.93; 95% CI 1.19–30.09; 0.007) [44]. One recent US registry analysis
has suggested that the effect of black ethnicity may be concentrated in
younger patients [46]. In an analysis of 112,120 patients transplanted
during 2000–2009, Schold et al. observed an increase in rejection risk
of 33% for African Americans in the 18–33 age group but no difference
compared to other ethnic groups in patients aged over 65 years [46].
Younger black recipients, in particular, appear to require relatively
intensive immunosuppression.
Morbidly obese patients (body mass index ≥35 kg/m2) may be
at higher risk for rejection but otherwise weight is not an inﬂuencing
factor [39]. Similarly, other clinical characteristics, including HIV infec-
tion [47], hepatitis C infection [38,48], cause of end-stage renal disease
[38], duration of dialysis [15] or the presence of diabetes [15,39] do
not signiﬁcantly affect the risk of rejection.
4. Donor graft characteristics
Historically, deceased-donor grafts have been associated with a
higher rate of rejection than those from living donors. Gore et al.
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Fig. 1.Association between acute rejection at one year after kidney transplantation and age of the recipient anddonor, based onUNOSdata from108,188patients transplantedduring1995
to 2008. Adapted from reference [37]. Reproduced with permission.
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ing 1997 to 1999, 33% of whichwere from living donors [39]. Recipients
of a living-donor graft were signiﬁcantly less likely to experience acute
rejection. However, the latest data reports from the US [9,49] show only
a 1%–2% increase in acute rejection rates for deceased-donor patients, so
under contemporary immunosuppressive regimens the type of donor
seems less inﬂuential. Living-related versus living-unrelated donation
does not affect rejection risk [50,51].
Single-center analyses have not suggested any adverse effect of ex-
panded criteria donation on rejection risk versus standard criteria grafts
[52,53], although recipients of an expanded criteria graft experience in-
ferior graft survival [54]. Similarly, the cause of donor death (brain
death or cardiac death) does not inﬂuence risk of rejection [55].
5. Adherence to medication
Non-adherence to the immunosuppressive regimen is, inevitably, a
major inﬂuence on rejection risk and is estimated to occur in a ﬁfth of
kidney transplant recipients [56]. In some cases, a high risk of non-
adherencemay be identiﬁable pre-transplant,warrantingmodiﬁcations
to the immunosuppressive regimen. Increasing recipient age positively
correlates with adherence [57,58]. In an analysis by Greenstein et al., re-
cipients aged less than 25 years were approximately 50%more likely to
be poorly adherent than older patients [57]. Adolescents are particularly
prone to poor adherence. A recent systematic review of 36 publications
found that the prevalence of non-adherence was 32% higher in adoles-
cents than in younger patients, and that almost one in four late acute re-
jection episodes was associated with non-adherence [59]. Other pre-
transplant clues to an increased risk for non- adherence include poor
attendance at dialysis sessions and, although less easy to deﬁne, atti-
tudes to pre-transplant medication taking, access to the pharmacy and
drug funding and social support [60–62].
6. Laboratory assessment of immunological risk
Historically, immunological risk was assessed solely on the basis of
T-cell or B-cell cross-matches and complement-dependent cytotoxic
(CDC) HLA antibody testing. A positive CDC cross-match has been
known for several decades to dramatically increase the host immuno-
logical response, with unacceptable rates of graft loss [63]. B-cell
cross-match, even with negative T-cell cross-match, is also highly
unfavorable [64]. Increasingly, however, it has been recognized that fol-
lowing the ﬁrst T-cell mediated response, B-cell activation and differen-
tiation lead to plasma cell production and generation of antibodies
which represent a late component of the immune cascade. Cross-
match testing still includes cytotoxic analysis, but for many years has
been supplemented by ﬂow cytometry or ELISA assays to measure
anti-donor antibodies. The increased risk for rejection in the presenceof HLA class I or II is well-established, regardless of donor speciﬁcity.
However, a major further step forward has been the development of
solid-phase single-bead antigen testing of solubilized HLA (Luminex®)
to detect HLA donor antigen speciﬁcities providing a far more nuanced
interpretation of immunological risk. Currently, immunologic risk is
typically based on a combination of results. For example, a patient
could be considered at intermediate risk if PRA was N5% and HLA anti-
bodies against speciﬁc HLA antigens were present, independent of
whether DSA could be determined, after a previous immunization
event such as pregnancy, blood transfusion or previous transplant
[65]. A patient with negative CDC, 200–250 mcs on ﬂow cytometry
and DSA N3000 mean ﬂuorescence intensity (MFI) would be regarded
as intermediate risk. A patient with high PRA (e.g. N25%), or speciﬁc
HLA antibodies after an early previous transplant lost due to immuno-
logical causes would be regarded as high risk and could be a candidate
for HLA-DSA desensitization.
New approaches are being developed whichmay help to further re-
ﬁne pre-transplant risk stratiﬁcation. These variously address the po-
tential contribution of different classes and intensities of HLA-DSA,
complement (C1q)-ﬁxing HLA-DSA, HLA non-DSA and non-HLA anti-
bodies, and their interactions. Several recent ﬁndings can already be
taken into account when evaluating risk. The presence of both
preformed DSA class I and class II at the time of transplant is associated
with a particularly high rate of graft loss [66]. Antibodies against non-
HLA targets have also emerged as a potentially important marker of
risk. Non-HLA antibodies against angiotensin type 1 (AT1) receptors
prior to transplant have been shown to increase the risk for humoral re-
jection [67,68] and irreversible graft injury [69]. Not all types of anti-
body are relevant to planning of the immunosuppression regimen,
however. Development of complement-ﬁxingDSA after transplantation
is associated with a particularly high risk for AMR and graft loss [70], for
instance, but occurs only rarely prior to transplantation [66].
New assays can also estimate cell-speciﬁc responses to engraftment.
Onewidely-testedmodality is the T-cell ELISPOT assay, whichmeasures
alloantigen-speciﬁc donor responsiveness as an estimate of immuno-
logical risk. Large validation studies from the US [71,72] and Europe
[73] have shown that a negative ELISPOT result indicates a ‘low re-
sponse’ patient in whom tolerogenic protocols could be pursued, al-
though the test is time-consuming and requires large volumes of
blood so may be best suited for living-donor recipients. Combined use
of several techniques, including more recent tests, permits accurate as-
sessment of risk. A minority of patients (e.g. 30%) who are negative for
HLA-antibodies and for HLA-DSA, for AT1 receptor antibodies, and for
a response on the ELISPOT assay can conﬁdently be regarded as low
risk, and immunosuppression tailored accordingly. Patients who are
negative for, or have a low level of, HLA antibodies overall, non-
cytotoxic HLA antibodies or evenHLA-DSA,with a lowormoderate pos-
itive result for anti-AT1 receptor antibodies but who have a positive
80 J. Pratschke et al. / Transplantation Reviews 30 (2016) 77–84ELISPOT test are at intermediate risk. Those with HLA DSA and who are
highly positive for AT1 receptor antibody and ELISPOT tests are at high
risk for AMR; those with low or intermediate DSA may be candidates
for desensitization protocols [68,74,75].
Pre-transplant serumconcentrations of the soluble CD30molecule, a
member of the tumor necrosis factor receptor superfamily, have also
shown promise as predictive markers for tubulitis in the graft [76], but
data are mixed concerning predictive value for AMR [76,77].
7. Sensitization after pregnancy
In a single-center study of 301 female kidney transplant patients
with at least one previous pregnancy, levels of HLA antibodies at each
HLA locus increased with the number of live births [78]. A smaller
single-center study, of 64 transplants with pre-formed DSA, found that
32% of the detected HLA speciﬁcities were induced by pregnancy, and
that the increase from pre-transplant DSA levels to the peak level by
day 30 post-transplant was higher for pregnancy-induced speciﬁcities
than for those induced by prior transfusion or transplantation [79]. Fe-
male patients with one, or particularly more than one, prior pregnancy
should be considered to be at least intermediate immunological risk
even if DSA level is low at time of transplant.
8. Immunologic risk after desensitization
Desensitization protocols are now used in more than half of US
transplant centers for sensitized living-donor kidney transplant candi-
dates [80]. Since desensitization is usually impractical in deceased-
donor transplants, the acceptable mismatch program successfully
practiced in the Eurotransplant allocation area represents a feasible al-
ternative approach. However, there is still no consensus regarding
which patients should receive desensitization, or the optimal combina-
tion, dose or timing of protocols [19,81]. Establishing the immunological
risk of a patient after desensitization treatment is challenging not only
because of this heterogeneity of approaches, but also because of the rel-
atively low numbers of patients to analyze. Orandi et al. analyzed rates
of graft loss in the largest cohort of desensitized living-donor recipients
so far, based on 1025 patients registered with United States Renal Data
System (USRDS) [82]. Graft loss after desensitization was far higher in
patients with positive cytotoxic cross-match than in those with positive
ﬂow cross-match (but negative cytotoxic cross-match). Patients who
tested positive on Luminex® but were negative for cytotoxic or ﬂow
cross-match showed only a slight increase in risk compared to compat-
ible transplants [82]. In a single-center analysis, Gloor et al. demonstrat-
ed that patients with cytotoxic cross-match have a high rate of AMR
(~50%) despite desensitization (Fig. 2) [83]. Even after intensive desen-
sitization using plasmapheresis, low-dose intravenous immunoglobulin0.2
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Fig. 2. Incidence of antibody-mediated rejection (AMR) in living-donor transplant patients w
(b300) ﬂow cross-match or no T-cell or B-cell cross‐match at the time of transplant, following d(IVIG), rituximab and pre-transplant immunosuppression, AMR has
been reported in more than 60% of living-donor patients with positive
cytotoxic cross-match [84]. Other authors have demonstrated that pos-
itive ﬂow cross-match [83], or higher mean ﬂow T-cell or B-cell cross-
match at time of transplant [85], increases the risk of AMR in
desensitized patients compared to patients with negative or low ﬂow
cross-match.
It appears that despite desensitization, an increased risk of AMR is
maintained although this is relatively low in DSA-positive patients
with negative cytotoxicity and ﬂow cross-match.
9. HLA matching
The impact of HLAmismatch on risk of acute rejection is undisputed
[15,38–40,86,87]. Transplants with no mismatches have a low risk of
cellular or AMR [10,15,38]. One large US registry study found that a pa-
tient receiving a kidney transplant with more than three HLA mis-
matches has more than a 50% increase in risk for acute rejection by
year 1 versus a zero-mismatch transplant [38]. Other authors have con-
ﬁrmed the signiﬁcant association between 4 and 6HLAmismatches and
risk for rejection [88]. HLA class II mismatch in DR loci is particularly un-
favorable [10,38,40,42] (Fig. 3). The risk of AMR appears to be increased
by HLA mismatching more than cellular rejection: one single-center
analysis found the HRs for antibody-mediated and cellular rejection to
be 5.00 and 1.86, respectively, for patients with ≥3 mismatches versus
zero mismatches [15].
10. Viral serostatus matching
Data from the 1990s suggested that cytomegalovirus (CMV) mis-
match was predictive for acute rejection after kidney transplantation
[89], but since the adoption of CMV prophylaxis in high-risk groups no
such link has been observed. One analysis of OPTN data from 24,216
transplants performed during 2004 to 2008 found no increase in the
risk for acute rejection in D+/R−, D−/R+ or D+/R+ transplants
compared to controls (D−/R−) [11]. Other authors have found onset
of CMV infection post-transplant to have no effect on borderline or
clinically-evident acute rejection [90,91].
Limited data on a possible association between Epstein–Barr
infection and rejection risk, largely from pediatric transplantation, are
inconclusive [92,93] and would not inﬂuence pre-transplant immuno-
suppression planning, although regardless of rejection risk the use of
belatacept is restricted to EBV-positive recipients. Development of BK
virus infection post-transplant can increase the risk of rejection due to
a consequent reduction in immunosuppressive intensity, but this does
not apply to the initial immunosuppression regimen, although it should
be borne in mind that maintenance therapy with tacrolimus and=30)
=37)
 (n=52)
transplant (days)
270 360 450 540
ith positive complement-dependent cytotoxicity (CDC) cross-match, high (N300) or low
esensitization protocols tailored according to risk level [83]. Reproducedwith permission.
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Fig. 3. Freedom fromantibody-mediated rejection by year 1 post-transplant in deceased-donor kidney transplants (1990–2010) according to number of HLAA or Bmismatcheswith 0HLA
DR mismatch, and number of HLA DR mismatches with 0 HLA A or B mismatch [10]. MM, mismatch. Reproduced with permission.
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thy [94–96].11. Organ preservation
Longer cold ischemia time is a well-documented risk factor for graft
loss after kidney transplantation, with every additional hour of cold is-
chemia increasing the risk of graft failure [97]. It has been estimated
that 30 h of hypothermic preservation increases the rate of graft loss
by 40% compared to six hours [97]. The impact of extended cold ische-
mia timearises fromexacerbated ischemia–perfusion injury and greater
risk of delayed graft function (DGF) [98,99], rather than through an in-
tensiﬁed host immunological response [100], but since DGF is an
established predictor for acute rejection long cold ischemia time can in-
directly affect rejection risk. Large single-center analyses [41,42,101]
have found small or non-signiﬁcant increases in risk for acute rejection
with each additional hour of hypothermic preservation when DGF was
taken into account. A US registry analysis published in 2006 found a
small signiﬁcant effect for long cold ischemia time (N24 h versus
≤24 h: adjusted risk ratio 1.04, p = 0.03), but such long preservation
times are now less frequent than in the past so the relevance of this is
questionable [102]. For living-donor recipients, cold ischemia longer
or shorter than 8 h has no effect on rejection rates [103]. In terms of
assessing immunological rejection, DGF appears to be a more directly
relevant risk factor than ischemic time.
It remains an open question whether the use of machine perfusion
lowers the risk for rejection. An international trial compared outcomes
in paired kidneys from the same donor after randomization to either
machine perfusion or cold storage [104]. The primary endpoint of DGF
was signiﬁcantly less likely with machine perfusion (odds ratio 0.57;
95% CI 0.36–0.88; p = 0.01) but acute rejection by year 1 was unaffect-
ed. Another multicenter randomized trial of paired donor kidneys, this
time from donors after cardiac death, again reported no difference in
acute rejection by one year using either type of preservation although
there was a trend to less rejection at three months withmachine perfu-
sion (7% versus 22%; p = 0.06) [105]. Overall, the literature does not
support a clear relationship between type of preservation system and
risk of rejection [104–106]. A post-hoc analysis of three randomized tri-
als reported a signiﬁcantly higher risk of acute rejection by one year for
donor kidneys with a shorter pump time compared to paired kidneys
with longer pump time (mean 22.7 h versus 31.2 h, p b 0.001) but this
interesting ﬁnding has not been substantiated by other studies.12. Delayed graft function
Delayed onset of graft function is generally believed to increase the
risk of subsequent acute rejection [1]. Ameta-analysis of 11 studies pub-
lished during 1994 to 2005, which enrolled a total of 4995 patients, cal-
culated the relative risk for acute rejection to be 1.46 (95% CI 1.29–1.47;
p b 0.001) for patients with DGF versus no DGF, when DGF was deﬁned
as any need for dialysis [107]. A large single-center analysis in amore re-
cent cohort (2000 to 2008) found that DGF using the more stringent
deﬁnition of more than one dialysis session increased the risk for
acute rejection to a greater extent (odds ratio 1.66; 95% CI 1.11–2.49;
p= 0.015) while patients requiring only one dialysis session had no in-
creased risk [107]. The degree to which the risk of rejection is increased
in the presence of DGF suggests that modiﬁcation of the planned initial
regimen should be amended depending on the timing of ﬁrst urine out-
put by the graft.
13. Deﬁning the early immunosuppression regimen
There are fourmain areas of decision-makingwhen planning the ini-
tial post-transplant regimen: (i) the possible use of pre-transplant de-
sensitization strategies [81] (ii) the use and type of induction therapy
[108] (iii) initiation of standard versus minimized CNI exposure from
time of transplant [109] and (iv) whether steroid avoidance (b7 days
administration) should be attempted [110]. A detailed discussion of
these early options – and longer-term immunosuppression regimens
based on the post-transplant course – is beyond the scope of this article.
Key points, however, are summarized in Table 1. As an example, a pa-
tient with preformed DSA receiving a second transplant is likely to be
a candidate for desensitization strategies while, at the other end of the
risk spectrum, a non-sensitized patient without positive indicators of
humoral sensitization may not beneﬁt from induction therapy [24], or
could be suitable for a steroid-avoidance regimen. A further point to
consider is the likely adherence of the patient to the prescribing regi-
men. As discussed above, non-adherence is highly predictive for rejec-
tion and graft loss, and where the risk of non-adherence appears high
aggressive CNI or steroid minimization strategies (or complex dosing
regimens) may be inadvisable.
14. Conclusion
The opportunities to tailor choice of induction therapy and the initial
maintenance immunosuppression after kidney transplantation have
82 J. Pratschke et al. / Transplantation Reviews 30 (2016) 77–84never been greater, requiring amore reﬁned pre-transplant assessment
of immunological risk than in the past. Transplant clinicians are faced
with amyriad of factors to consider, and although robust individualized
risk assessment is not yet feasible, patients can be stratiﬁed into differ-
ent immunological risk groups (Table 2). Some characteristics – such as
deceased donation and duration of cold ischemia time – have become
less important over time. Others confer only a minor increase in risk
or, indeed, have not consistently shown an effect, such as recipientTable 2
Overview of pre-transplant risk factors for acute rejection after kidney transplantation.
Risk factor Importance Comment
Recipient age
Younger age ++ Stronger immune response
Adolescence +++ Higher risk for non-adherence
Donor age + Trend towards higher immunogenicity in
older organs
Recipient gender + Trend to fewer rejections in males
Ethnicity +++ Signiﬁcantly higher risk of rejection in
African Americans
Deceased vs living
donor
+ Diminishing differences (also little
difference between deceased donation after
cardiac vs brain death, or expanded versus
criteria donation)
Previous transfusion + Considered ‘low immunologic responder’ if
patient is unsensitized despite previous
transfusion
Previous transplantation ++a No relevant increase in risk if the patient
remains unsensitized despite prior
transplantation. Early loss of previous graft
to immunological causes increases risk of
rejection after next graft
Previous pregnancy ++ Increasing risk with successive pregnancies
PRA N0% (HLA
antibodies)
+++ Applies to both historic and current PRA
level, HLA antibodies Class I and/or Class II
Preformed HLA DSA
(N500 MFI)
++++ Having no preformed HLA DSA at transplant
is associated with low immunological risk;
low levels of non-cytotoxic HLA antibodies
confer intermediate risk. De novo HLA DSA
post-transplant monitoring is required
AT1 receptor
antibodies
++ Test is relatively widely available
T-cell ELISPOT ++ Time-consuming (1–2 days) and requires
large blood volume; may be more relevant
for living-donor transplants
Soluble CD30 + Inconclusive data
Sensitized patients
after desensitization
++/+++ Increased risk of AMR appears to be
sustained after desensitization in DSA-
positive patients with negative cytotoxicity
and ﬂow cross-match, but to a far lesser
extent than in patients with positive
cytotoxic (profound increase in risk) or ﬂow
cross-match (moderate increase in risk)
HLA mismatch +++ Marked and well-documented effect on
cellular and antibody-mediated rejection.
Particularly pronounced for HLA DR
mismatch
CMV mismatch − No association between CMV mismatch and
acute rejection in the era of CMV
prophylaxis
EBV mismatch − No effect per se on acute rejection
Cold ischemia time + Less important with current shorter
ischemic times
Machine preservation + Minor effect versus cold storage; not well-
documented
Delayed graft function +++ Delayed function may prompt changes to
the planned protocol in the ﬁrst few days
post-transplant
CMV, cytomegalovirus; DSA, donor speciﬁc antibodies; EBV, Epstein Barr virus; HLA,
human leukocyte antigen; MFI, mean ﬂuorescence intensity; PRA, panel reactive
antibodies.
– Negligible or undocumented effect.
+ Mild effect or weak evidence.
++Moderate effect with acceptable evidence.
+++ Strong, well-documented effect.
a Only if the patient is sensitized.gender or presence of soluble CD30. A few conventional risk factors re-
main critical and should always be taken into account, notably the pres-
ence of HLA antibodies independent of DSA, and HLA mismatch
(particularly HLA DR and DQ mismatch). Increasingly, however, there
is a shift towards decision-making based on newer, more subtle pre-
transplant immunology tests. PRA monitoring has been superseded by
more subtle single-bead assays to detect the types of preformedHLA an-
tibodies. Non-HLA antibodies such as AT1R-Abs or ELISPOT testing are
likely to further reﬁne laboratory-based assessment of risk.
Algorithms which take into account the complexity of immune fac-
tors, together with pharmacogenetics and donor factors, could become
more relevant in the future and follow trends in other areas of precision
medicine [111].
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